Navigation Links
Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
Date:1/31/2013

ovel drugs for the treatment and diagnosis of cancer.  Our cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells.  Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells.  This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse.  I-124-CLR1404 (LIGHT) is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent.  We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing across 11 solid tumor indications.  I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells.  We believe HOT also has first-in-class potential.  HOT Phase 1b dose-escalation trial is ongoing and, subject to additional funding, we expect HOT to enter Phase 2 trials in the third quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need.  CLR1502 (GLOW2) is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.  Together, we believe our compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way.  For additional information please visit www.novelos.com

INVESTOR CONTACTS
J. Patrick Genn , Vice President of IR, Novelos Therapeutics, Inc., Madison, Wisc. & Boston, Mass., Ph: (858) 775-7456, Email: jpgenn@novelos.com

Anne Marie Fie
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Novelos Therapeutics Prices $5.4 Million Public Offering
4. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
5. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
6. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
7. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
9. Novelos Therapeutics Closes $2 Million Private Placement
10. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
11. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)... Resources Group finds that the rheumatoid arthritis (RA) disease-modifying antirheumatic drug ... billion in 2023 in the United States , ... Italy , Spain , the ... TNF-alpha inhibitors will remain the leading drug class in both sales ... constrained and patient shares will decline due to the uptake of ...
(Date:9/16/2014)... 16, 2014  Formex, LLC ("Formex"), a ... Mr. Greg Weilersbacher joined Formex as Director of ... Greg Weilersbacher has over ... expertise in Quality Assurance, Facility Validation, GMP ... brings to Formex a diverse wealth of ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... US Phase II Clinical Trials for Organ Transplantation, ... announces positive Phase I clinical results for,its transplantation ... clinical trials for organ transplantation. , Today LifeCycle ... I clinical trial program of LCP-Tacro, a,proprietary, once-daily ...
... Hemispherx Biopharma, Inc.,(AMEX: HEB), a biopharmaceutical company ... new drug entities for pandemic,disease threats, announced ... therapeutic product candidate Alferon-LDO in,combating highly pathogenic ... Alferon-LDO is a low-dose experimental oral formulation,of ...
Cached Medicine Technology:LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 2Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 3Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference 4
(Date:9/16/2014)... abnormalities in the adrenergic and noradrenergic systems, both ... play a role in the development of post-traumatic ... no genetic evidence of this connection. A collaborative ... Mailman School of Public Health and the University ... gene and childhood adversity. For individuals with two ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Beginning October 1st ... a new service offering for its clients who book a ... the volume of business they buy. Most recurring visit ... during the work week, but others include clients whose unique ... pet sitter on a daily basis. The newly ...
(Date:9/16/2014)... 16, 2014 The Pain Center ... by Ranking Arizona magazine, has selected Analance ™, ... enterprise. , With TPC seeing hundreds of thousands ... repository that was managed through “home grown” systems trying ... and clinical leadership teams. “Our current tools were ...
(Date:9/16/2014)... 2014 Founded by former Miami Beach ... a political organization fighting to legalize medical marijuana in ... The After Party recently commissioned a shot-for-shot parody video ... from the movie “Grease.” ( http://youtu.be/zdcvhUgeDRg ) , Called ... the musical parody faithfully recreates the carnival scene made ...
(Date:9/16/2014)... 16, 2014 Synergy Research Group has ... gives the best detail and analysis of the state ... a variety of sources, including Ministry of Health in ... will give readers actionable intelligence on clinical trials in ... relied on by the local and international life science ...
Breaking Medicine News(10 mins):Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 3Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3Health News:Miami Beach Politician Drives 1,400 Miles to Texas to Shoot “Grease” Parody Video Supporting the Legalization of Medical Marijuana in Florida 2Health News:Synergy Research Group Debuts Ukraine Orange Paper 2
... , THURSDAY, Jan. 6 (HealthDay News) -- The ... death in newborn intensive care units (NICUs) would be eligible ... infants and young children, according to a new study. ... of the more than 200,000 people in the United States ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Jan. ... February 2007 must be reviewed by the U.S. Food and ... the agency announced Wednesday. This effort, one aspect of ... meant to keep more addictive products from the hands of ...
... non-profit organization focused on supporting innovative early career ... its fall Fellowship Award Committee review. The ... postdoctoral scientists conducting basic and translational cancer research ... the country. The Fellowship encourages the nation,s most ...
... Jan. 5 (HealthDay News) -- Women with multiple sclerosis are ... gene thought to be connected to the condition, a new ... more insight into the development of MS, which is becoming ... Although no one knows what causes MS, scientists suspect that ...
... lateral sclerosis (ALS), and frontotemporal lobar degeneration (FTLD) are ... that include an RNA-binding protein called TDP-43. This protein ... by these clumps. In a study published ... team led by Virginia M.-Y. Lee, PhD, director of ...
... China are reporting development of a less expensive, more eco-friendly ... it may be a more healthful form of water. Their ... Chemistry Research . Changgong Meng and Feng Huang ... a mixture of H2O and tiny amounts of D2O ...
Cached Medicine News:Health News:Infant Organ Donors Could Help Meet Transplant Needs: Study 2Health News:FDA Launches Review of Tobacco Products 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 3Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 4Health News:Study Sheds Light on Genetic Risk of MS 2Health News:Malfunctioning gene associated with Lou Gehrig's disease leads to nerve-cell death in mice 2
Stylet tube, endotracheal, sterile, stainless steel, malleable, one size, overall length 13"(33cm)....
SunGlide™ Stylette - Green Adult. Use in 7.0 to 10mm tubes. 25/box....
SunGlide™ Stylette - Blue Neonatal. Use in 2.0 to 3.5mm tubes. 25/box....
Disposable Aluminum Satin Finish E/T Stylette, Adult 16, 25/box....
Medicine Products: